Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.98 |
| ▸ | PGR | P06401 | 3/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | AR | P10275 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | IKBKB | O14920 | 1/20 | 0.98 |
| ▸ | CHUK | O15111 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.98 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.98 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL588707 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1000080 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL28158165 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL719920 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL1868581 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11904933 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL4847833 | 0.99 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4847837 | 0.99 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234515-A | Methods and therapeutic compositions for treating and preventing severe injection site reactions | 腾盛博药生物科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-11969432-B2 | Pharmaceutical composition and use thereof | BARNAS, ARIAN JANKUR CAN (AT) | 2024-04-30 | — | — | US | claimed |
| CN-117771251-A | Moxifloxacin and dexamethasone sodium phosphate sustained-release ophthalmic gel and preparation method thereof | 上海昊海生物科技股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2023092046-A1 | PROCESS AND THERAPEUTIC COMPOSITION FOR TREATING AND PREVENTING SEVERE INJECTION SITE REACTIONS | BRII BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230149425-A1 | PROCESS AND THERAPEUTIC COMPOSITION FOR TREATING AND PREVENTING SEVERE INJECTION SITE REACTIONS | BRII BIOSCIENCES, INC. | 2023-05-18 | — | — | US | claimed |
| US-20220354870-A1 | READY-TO-USE BUPIVISONE PLUS LIQUID FORMULATION | LEITERS, INC. (US) | 2022-11-10 | — | — | US | claimed |
| WO-2022221534-A1 | READY-TO-USE BUPIVISONE PLUS LIQUID FORMULATION | LEITERS, INC. (US) | 2022-10-20 | — | — | WO | claimed |
| US-10736841-B2 | Bepotastine compositions | BAUSCH & LOMB INCORPORATED (US) | 2020-08-11 | — | — | US | claimed |
| EP-2800776-B1 | SILICONE ADHESIVE COMPOSITIONS | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-04-29 | — | — | EP | claimed |
| CN-104688746-B | A kind of preparation method of Gao Yuan Kang capsules | 中国人民解放军西藏军区总医院 | 2018-06-19 | — | — | CN | claimed |
| US-20040138113-A1 | Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action | ZYMOGENETICS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2003104807-A1 | USE OF CORTICOTROPH-DERIVED GLYCOPROTEIN HORMONE TO TREAT INFLAMMATION AND POTENTIATE GLUCOCORTICOID ACTION | ZYMOGENETICS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| EP-1331878-A1 | SUBCUTANEOUS SPIRAL ELECTRODE FOR SENSING ELECTRICAL SIGNALS OF THE HEART | Medtronic, Inc. (US) | 2003-08-06 | — | — | EP | claimed |
| US-6512940-B1 | Subcutaneous spiral electrode for sensing electrical signals of the heart | MEDTRONIC, INC. | 2003-01-28 | — | — | US | claimed |
| CN-1086126-C | Prednelan composition for treating rheumatism | LI ZHONG (CN) | 2002-06-12 | — | — | CN | claimed |
| WO-2002036000-A1 | SUBCUTANEOUS SPIRAL ELECTRODE FOR SENSING ELECTRICAL SIGNALS OF THE HEART | MEDTRONIC, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| US-6172053-B1 | Injection viral treatment | FIL-AM TECH, INC. | 2001-01-09 | — | — | US | claimed |
| CN-1254560-A | Prednelan composition for treating rheumatism | LI ZHONG (CN) | 2000-05-31 | — | — | CN | claimed |
| CN-1252003-A | Solvent system for enhancing permeation of pharmaceutical compounds | JOHNSON & JOHNSON CONSUMER (US) | 2000-05-03 | — | — | CN | claimed |
| CN-1183302-A | Eye drops contg. sodium hyaluronate and preparing method thereof | LING PEIXUE (CN) | 1998-06-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736841-B2 | Bepotastine compositions | IL5, CYP4B1, LTA4H | NR3C1 217/4885HIF1A 4647/4885CYP3A4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.